Today's Date: March 28, 2024
Ministry of Education and Science of Ukraine and Palantir Partner to Create Safe Conditions for In-Person Education in Schools   •   Parental avoidance of toxic exposures could help prevent autism, ADHD in children, new study shows   •   Government of Canada signs two bilateral agreements with Quebec to support initiatives to improve health care   •   The Lenserf Group Launches Emotional Intelligence Academy for HBCU Interns   •   Midea Group Breaks Revenue and Profit Records with RMB 373.7 Billion in 2023   •   Netcracker Continues Its Support of the U.S. Paralympic Ski and Snowboard Team at Adaptive Spirit 2024   •   Nutrex-Hawaii Introduces Its #1 Selling BioAstin® Hawaiian Astaxanthin® in a Retail-Ready, Sugar-Free, Vegan Gummy Forma   •   Clean Energy Appoints Patrick J. Ford to Board of Directors   •   EIG’s MidOcean Energy Completes Acquisition of Tokyo Gas’ Interests in Portfolio of Australian Integrated LNG Projec   •   Avnos and Deep Sky Forge Path to Gigaton-Scale Carbon Removal in Canada   •   The Home Depot Announces Agreement to Acquire SRS Distribution, a Leading Specialty Trade Distributor Across Multiple Verticals;   •   Latest U.S. Soybean Field Trials by Texas Crop Science Deliver Average Yield Increase of More Than 20%   •   PRIVATE SCHOOL VILLAGE (PSV) AWARDS INAUGURAL ELEMENTARY-SCHOOL SCHOLARSHIPS   •   Guo Guangchang: "Focus on building sustainable, predictable and enterprise with stable profit growth "   •   3EO Health Announces the First Point of Care Molecular Test Under $15   •   Cardinal Tobin Blesses New Open-Air Mausoleum of the Holy Spirit Site   •   Lenzing strives to drive beneficial transformation across the value chain   •   Apogee Enterprises Schedules Fourth Quarter Fiscal Year 2024 Earnings Release and Conference Call   •   Stora Enso publishes Green and Sustainability-Linked Financing Report 2023   •   Chris Diehl Returns to 101 Mobility as Director of National Accounts
Bookmark and Share

Aura Biosciences to Participate in Upcoming Investor Conferences

BOSTON , February 09 /Businesswire/ - Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:

  • SVB Securities Global Biopharma Conference on Thursday, February 16, 2023.

    Fireside Chat at 12:00 p.m. ET.
  • 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023.

    Auditory & Ophthalmology Panel Discussion at 12:50 p.m. ET.

Live webcasts of the SVB fireside chat and Cowen panel discussion will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology indications. Aura’s lead VDC candidate, belzupacap sarotalocan (bel-sar; AU-011), consists of a virus-like particle conjugated with an anti-cancer agent. Bel-sar is designed to selectively target and destroy cancer cells and activate the immune system with the potential to create long-lasting anti-tumor immunity. Bel-sar is currently in development for ocular cancers, and Aura has initiated activities for the global Phase 3 trial evaluating first-line treatment of early-stage choroidal melanoma, a vision- and life-threatening form of eye cancer where standard of care with radiotherapy leaves patients with severe comorbidities, including major vision loss. Aura plans to pursue development of bel-sar across its ocular oncology franchise including for the treatment of patients with choroidal metastasis. In addition, leveraging Aura’s technology platform, Aura is developing bel-sar more broadly across multiple cancers, including in patients with non-muscle invasive bladder cancer (NMIBC). Aura is headquartered in Boston, MA.


STORY TAGS: Conference, Webcast, United States, North America, Research, FDA, Clinical Trials, Biotechnology, Pharmaceutical, Health, Optical, Science, Oncology, Other Science, Massachusetts,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News